$OPK I for one, firmly believe Frost knows Rayaldee as a CV19 treatment is a money losing endeavor; hence, OPKs desire to use CKD patients w/CV. This CKD trial will help introduce Rayaldee to Nephrologists and expose its inherent attributes to increase prescription sales and gain more CKD data. The govt could be picking up part of the tab too. Another viewpoint to consider is the reduced amount of potential patients who will benefit from a vaccine and will not need treatments whatsoever (albeit, those vaccines will not be a cure all). And, by the time Rayaldee could be approved.... the population will be getting vaccinated. Don’t get me wrong, I truly wish they would Emergency Approve Rayaldee overnight... but I don’t see at this juncture.